GlassScriptPhysician profile
Cortie John Rolison
NPI 1184986671
$2,459.25
in general payments reported to CMS, 2019-2025
25 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.59 · 2021: $18.42 · 2022: $563 · 2023: $593 · 2024: $670 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.26 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $383.79 | 2022-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $284.19 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $253.56 | 2022-2025 | |
| Abbvie INC. | $137.36 | 2022-2024 | Ubrelvy |
| Glaxosmithkline, LLC. | $113.77 | 2020-2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $103.55 | 2025 | Inspire |
| Amgen INC. | $94.24 | 2023-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $76.57 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $59.08 | 2022 | |
| Exact Sciences Corporation | $49.60 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.20 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $42.00 | 2024 | Trintellix |
| Axsome Therapeutics, INC. | $27.93 | 2023 | Auvelity |
| Currax Pharmaceuticals LLC | $27.88 | 2022-2023 | Contrave |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $26.20 | 2024 | |
| Merck Sharp & Dohme LLC | $26.07 | 2025 | Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.29 | 2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $24.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.93 | 2022 | |
| Bardy Diagnostics, INC. | $18.42 | 2021 | |
| Indivior INC. | $17.93 | 2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $17.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.38 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $13.14 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortie Rolison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.